Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408871 · ClinicalTrials.gov registry record · Phase 1
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05408871 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants.
The verdict
NCT05408871, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using \[a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within resected lesions in head and neck cancer and brain metastases.
Interventions
- DRUG adnectin 18F-BMS-986192 Head and Neck Cancer
- DRUG adnectin 18F-BMS-986192 Brain Metastases
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408871
The ClinicalTrials.gov registry entry for NCT05408871 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adnectin 18F-BMS-986192 Head and Neck Cancer is the first listed.
NCT05408871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05408871 about?
NCT05408871 is a clinical study titled "Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases". This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using \[a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within resected lesions in head and neck cancer and brain metastases.
What is the current status of trial NCT05408871?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-02-21. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT05408871?
The interventions under investigation include: adnectin 18F-BMS-986192 Head and Neck Cancer (DRUG), adnectin 18F-BMS-986192 Brain Metastases (DRUG).
Who is sponsoring clinical trial NCT05408871?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.